Bayer and Us Too! Collaborate on Support for Advanced Prostate Cancer Patients

Publication
Article
OncologyONCOLOGY Vol 16 No 9
Volume 16
Issue 9

The Bayer Corporation recently announced that it has teamed up with Us Too! International to offer Continuous Care, a program for advanced prostate cancer patients using the leuprolide acetate implant (Viadur). The program provides appointment reminders, education, support materials, and valuable health coupons.

The Bayer Corporationrecentlyannounced that it has teamedup with Us Too! International to offer Continuous Care, a program for advancedprostate cancer patients using the leuprolide acetate implant (Viadur). Theprogram provides appointment reminders, education, support materials, andvaluable health coupons.

"Us Too! encourages voluntary programs (such as Bayer’sContinuous Care program) that seek to disseminate information and provideongoing support to those affected by prostate cancer," said John A. Page,fhimss, president and CEO, Us Too!. "We appreciate the opportunity to workwith a company so dedicated to men’s health, and look forward to continuingour commitment to meeting the needs of prostate cancer patients and theirfamilies."

Annual Implantation

"Because the annual implantation of Viadur is just oneaspect of a comprehensive approach to patient management, Continuous Care offerspatients year-long support and education and helps them stay on track with theirtreatment program," said Nancy Bryan, vice president, Bayer Men’s Health."And with the help of Us Too!, we will further enhance patient support,thereby strengthening our commitment to help those with advanced prostatecancer."

The implant delivers a continuous 12-month infusion ofleuprolide, which is a luteinizing hormone-releasing hormone (LHRH) agonist, topatients with advanced prostate cancer. More information about the implant andits mechanism of action can be found at http://viadur.com.

The most common systemic side effects associated with the use of theleuprolide implant include hot flashes (67.9%), asthenia (7.6%), gynecomastia(6.9%), depression (5.3%), and sweating (5.3%). The most common local sideeffects are bruising (34.6%) and burning (5.6%).

Related Videos
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content